Clinical Trial Search

Primary: Geometric Mean Titers (GMTs) of Tetanus, Diphtheria, and Pertussis Antibodies Pre- and Post-Vaccination With ADACEL® or DECAVAC® Vaccine — 0.501; 0.451; 8.43; 7.23 Titers

Primary: Number of Participants With Adverse Reactions — 80; 1 Participants

Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001

Primary: Absolute Vaccine Efficacy (VE) of aQIV Versus Non-influenza Comparator Based on RT-PCR-confirmed Influenza Due to Any Strain Using Protocol Defined ILI Definition…

Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 2; 2; 1; 0 Participants

Primary: RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group — 7906.0; 7518.9 Titer

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells

Primary: Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative Participants — 87.3; 1.1 percentage of participants — p=<0.0001

Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…

Primary: PROMIS Global Health Measure Score — 46.27; 46.21; 44.92; 46.38 T-score

Primary: Stage 1: Percentage of Participants With Local Reactions Within 14 Days After Vaccination — 2.9; 12.5; 2.9; 6.3 percentage of participants

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination — 7.9; 2.5; 8.6; 12.7 percentage of participants

Primary: Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies — 30 Participants

Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV — 46; 89; 43; 90…

Primary: Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine. — 40.5; 28.8; 36.4; 41.4 1/dilution…

Primary: Number of Participants With Immediate Unsolicited Adverse Events (AE) After Vaccination — 0; 0; 0 Participants

Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) for the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HI) Assay and for A/H3N2…

Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVc — 66; 41; 98; 84…

Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC): Injection Site (Arm and Thigh) Versus Abdominal Wall Injection (Cohort A) — 124000; 133000; 135000…

Primary: HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination — 175; 117; 144; 118 Titer

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 — 7.3; 3.6; 3.6; 3.2 percentage of participants

Primary: Number of Subjects (3 to <9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine. — 31; 36; 18; 24 Number of Subjects

Primary: Haemagglutination Inhibition (HI) Antibody Titers for the H1N1 Vaccine Strain — 37.9; 40.1; NA; NA titer

Primary: Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths — 18; 19; 22; 20 Participants

Primary: Overall Survival — 19.2 Months

Primary: Enrollment — 22; 20; 18; 42 Participants

Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 1; 2; 3; 3 Participants

Primary: Treatment Emergent AEs During 7 Days After Experimental Treatment — 1; 0; 12; 3 Participants

Primary: Overall Response Rate (ORR) — 39 participants